Results 161 to 170 of about 7,834 (208)

Combination Therapy Using Phytochemicals and PARP Inhibitors in Hybrid Nanocarriers: An Optimistic Approach for the Management of Colon Cancer. [PDF]

Int J Mol Sci
Qureshi MJ, Narde GK, Ahuja A, Meenakshi DU, Al Balushi K.   +4 more
europepmc   +1 more source

PARP1 inhibitors regulate PARP1 structure independent of DNA, reducing binding affinity for single strand breaks

Pailing M, van Beek L, Maia de Oliveira T, Flocco MM, Hoogenboom BW.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Talazoparib nanoparticles for overcoming multidrug resistance in triple‐negative breast cancer

Journal of Cellular Physiology, 2020
AbstractHerein, we investigated efflux pumps‐mediated talazoparib‐resistance in the treatment of triple‐negative breast cancer (TNBC). Furthermore, we produced a novel talazoparib‐solid lipid nanoparticles (SLNs) and then explored in vitro therapeutic efficacy of talazoparib‐SLNs to overcome talazoparib‐resistance in TNBC cells.
Gamze Guney Eskiler, Gülşah Cecener, Ünal Egeli   +2 more
exaly   +5 more sources

Talazoparib (Talzenna) for Prostate Cancer

The Medical Letter on Drugs and Therapeutics, 2023
The oral poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib (Talzenna – Pfizer) has been approved by the FDA for use in combination with the androgen receptor blocker enzalutamide (Xtandi) for treatment of adults with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
openaire   +2 more sources

Talazoparib: First Global Approval

Drugs, 2018
Talazoparib (TALZENNA™) is an oral inhibitor of the polyadenosine 5'-diphosphoribose polymerase (PARP) enzymes, which play a critical role in repairing DNA single-strand breaks. It has been developed by Pfizer and was recently approved in the USA for the treatment of adults with deleterious or suspected deleterious germline BRCA-mutated, human ...
openaire   +5 more sources

Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer

The Journal of Clinical Pharmacology, 2019
AbstractPoly(ADP‐ribose) polymerase (PARP) inhibitors have been developed to treat cancers associated with somatic BRCA mutations and germline genetic aberrations involved in the DNA damage response. The efficacy, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profile of talazoparib, a potent small‐molecule PARP inhibitor, was established in
Yanke, Yu, Chandrasekar, Durairaj, Haihong, Shi, Diane D, Wang   +3 more
openaire   +2 more sources

Talazoparib for the treatment of prostate cancer

Expert Opinion on Pharmacotherapy
Around 25% of patients with advanced prostate cancer harbor alterations in the homologous recombination/DNA damage repair (HRR) pathway. Inhibiting poly (ADP-ribose) polymerase (PARP) in these patients leads to synthetic lethality, making PARP inhibitors (PARPi), including talazoparib, a promising treatment for metastatic castration-resistant prostate ...
Arshit, Narang, Chadi, Hage Chehade, Zeynep Irem, Ozay, Blake, Nordblad, Umang, Swami, Neeraj, Agarwal   +5 more
openaire   +2 more sources

Abstract OT2-03-04: A trial of induction Talazoparib followed by a combination of Talazoparib and Avelumab in advanced breast cancer: The TALAVE study

Cancer Research, 2020
Abstract Background: Patients with advanced breast cancer (ABC) have recently gained access to promising new therapies, including PARP inhibitors (PARPi) and immunotherapy. However, not all patients benefit from these approaches, with response rates highest in patients characterized by a particular biomarker (ie BRCA1/2 mutation or PD-L1
Arielle L Heeke, Michael Pishvaian, Hongkun Wang, Adam Cohen, Jeffrey Schlom, Renee Donahue, Caroline Jochems, Margaret Gatti-Mays, Paula Pohlmann, Antoinette Tan, Claudine Isaacs, Filipa Lynce   +11 more
openaire   +1 more source